Detailed description page of THPdb

This page displays user query in tabular form.

1529 details

Primary information
ThPP ID	Th1108
Therapeutic Peptide/Protein Name	Pegaptanib
Sequence	N.A. view full sequnce in fasta
Functional Classification	IIa
Molecular Weight	N.A.
Chemical Formula	N.A.
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	10 Â± 4 days
Description	It is a polynucleotide aptamer, which specifically binds to VEGF 165, a protein that plays a critical role in angiogenesis and increased permeability of blood vessels; two of the primary pathological processes responsible for vision loss associated with neovascular AMD. [Wikipedia]
Indication/Disease	For the treatment of neovascular (wet) age-related macular degeneration.
Pharmacodynamics	Pegaptanib is a selective vascular endothelial growth factor (VEGF) antagonist. VEGF is a secreted protein that selectively binds and activates its receptors located primarily on the surface of vascular endothelial cells. VEGF induces angiogenesis, and increases vascular permeability and inflammation, all of which are thought to contribute to the progression of the neovascular (wet) form of age-related macular degeneration (AMD), a leading cause of blindness. VEGF has been implicated in blood retinal barrier breakdown and pathological ocular neovascularization.
Mechanism of Action	Pegaptanib binds to the major pathological VEGF isoform, extracellular VEGF165, thereby inhibiting VEGF165 binding to its VEGF receptors. The inhibition of VEGF164, the rodent counterpart of human VEGF165, was effective at suppressing pathological neovascularization.
Toxicity	Most common adverse reactions associated with the use of lucinactant are endotracheal tube reflux, pallor, endotracheal tube obstruction, and need for dose interruption.
Metabolism	Based on preclinical data, pegaptanib is metabolized by endo- and exonucleases.
Absorption	In animals, pegaptanib is slowly absorbed into the systemic circulation from the eye after intravitreous administration.
Volume of Distribution	N.A.
Clearance	N.A.
Categories	Intended for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	Pulmonary
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	Macugen
Company	Gilead Sciences
Brand Discription	Pegaptanib sodium is a covalent conjugate of an oligonucleotide of twenty-eight nucleotides in length that terminates in a pentylamino linker, to which two 20-kilodalton monomethoxy polyethylene glycol (PEG) units are covalently attached via the two amino groups on a lysine residue.
Prescribed for	Macugen is indicated for the treatment of neovascular (wet) age-related macular degeneration.
Chemical Name	N.A.
Formulation	Macugen is supplied in a single-dose, pre-filled syringe and is formulated as a 3.47 mg/mL solution, measured as the free acid form of the oligonucleotide. The active ingredient is 0.3 mg of the free acid form of the oligonucleotide without polyethylene glycol, in a nominal volume of 90 Î¼L. This dose is equivalent to 1.6 mg of pegaptanib sodium (pegylated oligonucleotide) or 0.32 mg when expressed as the sodium salt form of the oligonucleotide moiety. The product is a sterile, clear, preservative-free solution containing sodium chloride, monobasic sodium phosphate monohydrate, dibasic sodium phosphate heptahydrate, hydrochloric acid, and/or sodium hydroxide to adjust the pH and water for injection.
Physcial Appearnce	Sterile, aqueous solution containing pegaptanib sodium for intravitreous injection
Route of Administration	Intravitreal Injection ONLY
Recommended Dosage	Macugen 0.3 mg should be administered once every six weeks into the eye to be treated.
Contraindication	Ocular or Periocular Infections: Macugen is contraindicated in patients with ocular or periocular infections.Hypersensitivity to pegaptanib sodium or any other excipient in this product.
Side Effects	The most frequently reported adverse events in patients treated with Macugen 0.3 mg for up to two years were anterior chamber inflammation, blurred vision, cataract, conjunctival hemorrhage, corneal edema, eye discharge, eye irritation, eye pain, hypertension, increased intraocular pressure (IOP), ocular discomfort, punctate keratitis, reduced visual acuity, visual disturbance, vitreous floaters, and vitreous opacities; Ocular: blepharitis, conjunctivitis, photopsia, vitreous disorder.; Non-Ocular: bronchitis, diarrhea, dizziness, headache, nausea, urinary tract infection.
Useful Link	http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=43224 http://www.bausch.com/ecp/our-products/rx-pharmaceuticals/rx-pharmaceuticals/macugen-pegaptanib-sodium-injection#.VP2PHculi1E http://www.rxlist.com/macugen-drug.htm
PubMed ID	17717967, 17693999, 17687925, 23560774
3-D Structure	N.A.